Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide and Ibrutinib with R-MPV in Primary Central Nervous System Lymphoma
NCT04446962Phase 2Active, not recruiting
- Sponsor
- Institut Curie
- Start
- Oct 2020
- Primary completion
- Feb 2035
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in primary central nervous system lymphoma (PCNSL) comparing Arm A: R-MPV with Lenalidomide with Arm B: R-MPV with Ibrutinib (2 arms). Primary endpoints: Dose Limiting Toxicity at 1 month and Complete Response rate at 4 months. Started Oct 2020; status: active, not recruiting.
02
Drugs
lenalidomideibrutinib
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT04446962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04446962.